Literature DB >> 24890460

HSP70 inhibits high glucose-induced Smad3 activation and attenuates epithelial-to-mesenchymal transition of peritoneal mesothelial cells.

Jun Liu1, Jinfang Bao1, Jing Hao1, Yan Peng1, Fuyuan Hong2.   

Abstract

Heat shock proteins (HSPs) are molecular chaperones that were initially identified as proteins expressed following exposure of cells to environmental stress. However, the function of HSPs in epithelial‑to‑mesenchymal transition (EMT) of peritoneal mesothelial cells remains unknown. In the present study, the regulation of HSPs and their function in cell EMT, particularly in rat peritoneal mesothelial cells (RPMCs), and the surrounding glucose concentrations and the molecular mechanism involved were investigated. This study explored the effect of HSP70 on high glucose (HG)-induced EMT by overexpression and small interfering RNA (siRNA) knockdown of HSP70, as well as the underlying molecular mechanisms. It was found that HSP70 inhibits HG-induced EMT by modulating Smad expression and activation. HSP70 overexpression inhibited phosphorylation and nuclear translocation of p-Smad3 and p-Smad4, while siRNA of HSP70 enhanced HG‑induced Smad3 and Smad4 phosphorylation and EMT. Furthermore, HSP70 suppressed EMT by inhibiting the generation of reactive oxygen species (ROS) induced by HG. In conclusion, HSP70 inhibits EMT of peritoneal mesothelial cells primarily by exerting domain‑specific effects on Smad3 and Smad4 activation and reducing the release of ROS. HSP70 may be a novel therapeutic target for peritoneal dialysis patients with peritoneal fibrosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24890460     DOI: 10.3892/mmr.2014.2279

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  8 in total

Review 1.  Cytosolic protein quality control machinery: Interactions of Hsp70 with a network of co-chaperones and substrates.

Authors:  Chamithi Karunanayake; Richard C Page
Journal:  Exp Biol Med (Maywood)       Date:  2021-03-17

2.  Suppression of AGR2 in a TGF-β-induced Smad regulatory pathway mediates epithelial-mesenchymal transition.

Authors:  Lucia Sommerova; Eva Ondrouskova; Borivoj Vojtesek; Roman Hrstka
Journal:  BMC Cancer       Date:  2017-08-15       Impact factor: 4.430

3.  Effect of astragaloside IV and the role of nuclear receptor RXRα in human peritoneal mesothelial cells in high glucose‑based peritoneal dialysis fluids.

Authors:  Weiwei Zhu; Xin Zhang; Kun Gao; Xufang Wang
Journal:  Mol Med Rep       Date:  2019-08-22       Impact factor: 2.952

Review 4.  HSP70 Multi-Functionality in Cancer.

Authors:  Zarema Albakova; Grigoriy A Armeev; Leonid M Kanevskiy; Elena I Kovalenko; Alexander M Sapozhnikov
Journal:  Cells       Date:  2020-03-02       Impact factor: 6.600

5.  Extracellular Hsp70 Reduces the Pro-Tumor Capacity of Monocytes/Macrophages Co-Cultivated with Cancer Cells.

Authors:  Elena Y Komarova; Larisa V Marchenko; Alexander V Zhakhov; Alina D Nikotina; Nikolay D Aksenov; Roman V Suezov; Alexander M Ischenko; Boris A Margulis; Irina V Guzhova
Journal:  Int J Mol Sci       Date:  2019-12-20       Impact factor: 5.923

6.  Smad3 signalling affects high glucose-induced podocyte injury via regulation of the cytoskeletal protein transgelin.

Authors:  Lina Jiang; Hong Cui; Jie Ding
Journal:  Nephrology (Carlton)       Date:  2020-03-05       Impact factor: 2.506

Review 7.  The Epithelial-to-Mesenchymal Transition (EMT) in the Development and Metastasis of Malignant Pleural Mesothelioma.

Authors:  Valeria Ramundo; Giada Zanirato; Elisabetta Aldieri
Journal:  Int J Mol Sci       Date:  2021-11-11       Impact factor: 5.923

8.  Salidroside inhibits the proliferation and migration of gastric cancer cells via suppression of Src‑associated signaling pathway activation and heat shock protein 70 expression.

Authors:  Zhilin Qi; Tuo Tang; Lili Sheng; Yunfei Ma; Yinhua Liu; Liang Yan; Shimei Qi; Liefeng Ling; Yao Zhang
Journal:  Mol Med Rep       Date:  2018-05-03       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.